Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay
Zomedica (OTCQB:ZOMDF) has expanded its TRUFORMA diagnostic platform by adding feline testing capability to its cobalamin & folate assay, previously only available for canine patients. The multiplexed assay, which combines two critical tests in one, delivers results in under 25 minutes at the point of care.
Originally launched for dogs in early 2024, this first-of-its-kind in-clinic test now addresses the critical need for rapid diagnosis in feline patients with gastrointestinal conditions. According to veterinary experts, this expansion is particularly significant as feline patients with GI disease often deteriorate more rapidly than canine patients, making quick results crucial for timely treatment.
Zomedica (OTCQB:ZOMDF) ha ampliato la sua piattaforma diagnostica TRUFORMA introducendo la possibilità di test felini per l’analisi di cobalamina e folato, precedentemente disponibile solo per i cani. Il test multiplex, che combina due analisi importanti in una, fornisce risultati in meno di 25 minuti sul posto.
Lanciato originariamente per i cani all’inizio del 2024, questo test in-clinic unico nel suo genere risponde ora al bisogno cruciale di una diagnosi rapida nei pazienti felini con condizioni GI. Secondo gli esperti veterinari, questa espansione è particolarmente significativa poiché i gatti con malattie GI tendono a deteriorarsi più rapidamente rispetto ai cani, rendendo essenziali risultati rapidi per un trattamento tempestivo.
Zomedica (OTCQB:ZOMDF) ha ampliado su plataforma diagnóstica TRUFORMA añadiendo la capacidad de realizar pruebas felinas para el análisis de cobalamina y folato, que anteriormente solo estaban disponibles para perros. La prueba multiplex, que une dos pruebas críticas en una, entrega resultados en menos de 25 minutos in situ.
Originalmente lanzada para perros a principios de 2024, esta prueba clínica pionera ahora atiende la necesidad crítica de un diagnóstico rápido en pacientes felinos con afecciones gastrointestinales. Según expertos veterinarios, esta expansión es especialmente significativa ya que los pacientes felinos con enfermedad GI a menudo se deterioran más rápido que los caninos, haciendo que los resultados rápidos sean cruciales para un tratamiento oportuno.
Zomedica (OTCQB:ZOMDF)가 TRUFORMA 진단 플랫폼을 확장하여 고양이용 검사 기능을 cobalamin(비타민 B12) 및 folate(엽산) 검사에 추가했습니다. 이전에 오직 개에게만 제공되던 이 다중 검사(multiplexed assay)는 하나의 검사로 두 가지 중요한 테스트를 결합하며 현장에서 25분 이내에 결과를 제공합니다.
개를 대상으로 2024년 초에 처음 출시된 이 클리닉 내 테스트는 이제 GI 질환을 가진 고양이 환자에 대한 신속한 진단의 필요성을 충족합니다. 수의학 전문가에 따르면 이 확장은 특히 의미가 있는데, GI 질환이 있는 고양이가 개보다 빠르게 악화되는 경향이 있어 신속한 결과가 시의적절한 치료에 결정적이라고 합니다.
Zomedica (OTCQB:ZOMDF) a étendu sa plateforme diagnostique TRUFORMA en ajoutant la possibilité de tester les félins pour l’analyse de la cobalamine et des folates, auparavant disponible uniquement pour les chiens. Le test multiplex, qui combine deux analyses clés en une, fournit les résultats en moins de 25 minutes sur le lieu de soin.
Initialement lancé pour les chiens au début de 2024, ce test in-clinic pionnier répond désormais au besoin critique d’un diagnostic rapide chez les patients félins souffrant de maladies gastro-intestinales. Selon les experts vétérinaires, cette expansion est particulièrement significative car les chats atteints de troubles GI tendent à se détériorer plus rapidement que les chiens, rendant les résultats rapides cruciaux pour un traitement en temps utile.
Zomedica (OTCQB:ZOMDF) hat seine TRUFORMA-Diagnostikplattform erweitert, indem eine felinische Testmöglichkeit für den Cobalamin- und Folat-Test hinzugefügt wurde, der zuvor nur für Hunde verfügbar war. Der multiplexierte Test, der zwei wichtige Untersuchungen in einem kombiniert, liefert die Ergebnisse in weniger als 25 Minuten direkt vor Ort.
Ursprünglich Anfang 2024 für Hunde eingeführt, adressiert dieser erstmalige In-Clinic-Test nun den dringenden Bedarf an schneller Diagnose bei felinen GI-Erkrankungen. Fachleute weisen darauf hin, dass diese Erweiterung besonders bedeutsam ist, da Katzen mit GI-Erkrankungen oft schneller verschlechtern als Hunde, was schnelle Ergebnisse für eine zeitnahe Behandlung entscheidend macht.
Zomedica (OTCQB:ZOMDF) قامت بتوسيع منصتها التشخيصية TRUFORMA بإضافة إمكانية فحص القطط إلى اختبارها للكوبالامين والفولات، الذي كان متاحاً سابقاً فقط للكلاب. الاختبار المتعدد، الذي يجمع اختبارين مهمين في واحد، يوفر النتائج في أقل من 25 دقيقة في مكان الرعاية.
تم إطلاقه أصلاً للكلاب في أوائل 2024، وهذا الاختبار الأول من نوعه داخل العيادة الآن يخدم الحاجة الملحة لتشخيص سريع لدى مرضى القطط الذين يعانون من حالات جهاز هضمي. وفقاً للخبراء البيطريين، فإن هذا التوسع ذو أهمية خاصة لأن القطط المصابة بأمراض GI غالباً ما تتدهور بسرعة أكبر من الكلاب، مما يجعل النتائج السريعة حاسمة للعلاج الفوري.
Zomedica（OTCQB:ZOMDF） 已通过在其 TRUFORMA 诊断平台中增加针对猫科的检测能力，扩展了对体内维生素B12（钴胺）与叶酸检测的猫科适用性，此前仅面向犬只。该多重检测把两项关键测试合并为一，在现场 25 分钟内完成出结果。
该测试最初于 2024 年初为犬只推出，如今成为诊所内的首创测试，满足患有胃肠道疾病的猫科患者对快速诊断的迫切需求。兽医专家指出，这一扩展尤为重要，因为患 GI 疾病的猫往往比犬类恶化更快，快速得到结果对及时治疗至关重要。
- None.
- None.
Insights
Zomedica expands its diagnostic capabilities to feline market, strengthening its competitive position in veterinary point-of-care testing.
Zomedica's expansion of their TRUFORMA platform to include feline testing for cobalamin and folate represents a strategic market expansion that addresses an unmet clinical need. The addition to their previously canine-only assay significantly increases the platform's utility and market potential, as feline gastrointestinal cases represent a substantial portion of veterinary visits.
This multiplexed assay offers a critical clinical advantage by delivering results in under 25 minutes, compared to the traditional reference lab turnaround of 1-3 days. This speed advantage is particularly valuable for feline patients who, as noted by the cited veterinary internal medicine specialist, often deteriorate more rapidly than dogs with similar conditions. The point-of-care capability enables immediate treatment decisions during the initial visit—a workflow improvement that benefits both patient outcomes and clinic efficiency.
From a competitive standpoint, Zomedica maintains its position as the only provider offering this dual-marker test in-clinic. This exclusivity creates a meaningful differentiator in the veterinary diagnostics market, which has become increasingly competitive. By expanding to feline applications, Zomedica has effectively doubled the addressable market for this particular assay while leveraging their existing platform technology and customer relationships.
The expansion aligns with the company's strategy of building a comprehensive diagnostic ecosystem through the TRUFORMA platform, with each additional test increasing the overall value proposition to veterinary clinics that have invested in the system. This platform-based approach typically yields higher customer retention and recurring revenue through consumable test cartridge sales, enhancing long-term revenue stability.
First and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients
ANN ARBOR, MI / ACCESS Newswire / September 23, 2025 / Zomedica Corp. (OTCQB:ZOMDF) ("Zomedica" or the "Company"), a veterinary health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin & folate assay.
Originally launched in early 2024 for canine use, this multiplexed assay-combining two critical tests in one-was the first of its kind to bring both cobalamin and folate testing to the in-clinic setting. Since that time, veterinarians have expressed strong demand to extend this capability to their feline patients.
Highlighting the clinical importance of this expansion, Deborah Greco, DVM, PhD, DACVIM, commented: "Feline patients with gastrointestinal disease often deteriorate more rapidly than canine patients, making timely and accurate results even more critical. Having access to cobalamin and folate results in under 25 minutes enables veterinarians to initiate or adjust treatment during the same visit-improving both clinical outcomes and the quality of care."
"We launched the canine cobalamin & folate multiplexed assay knowing that non-infectious gastrointestinal conditions such as vomiting and diarrhea are among the most common reasons for veterinary visits," noted Michael Mockler, Senior Product Manager for Zomedica. "Before the introduction of the TRUFORMA platform, veterinarians had no reliable in-clinic option for these tests. Now, they can quickly assess two important biomarkers at the point of care, improving diagnostic efficiency, enhancing workflow, and supporting practice profitability. Expanding this capability to cats represents an important step forward in addressing a critical clinical need."
With this new capability, TRUFORMA continues to provide veterinarians with advanced, in-clinic testing solutions that deliver reference-lab quality results in minutes, empowering faster, more informed decisions for both canine and feline patients.
The TRUFORMA cobalamin & folate test is available directly from Zomedica, either through the myZomedica online portal or Zomedica Customer Service at (734) 369-2555 or info@zomedica.com.
For more information on Zomedica please visit www.zomedica.com.
About Zomedica
Zomedica is a leading equine and companion animal healthcare company dedicated to improving animal health by providing veterinarians with innovative therapeutic and diagnostic solutions. Our gold standard PulseVet® shock wave system, which accelerates healing in musculoskeletal conditions, has transformed veterinary therapeutics. Our suite of products also includes the Assisi® Loop line of therapeutic devices and the TRUFORMA® diagnostic platform, the TRUVIEW® digital cytology system, and the VetGuardian® no-touch monitoring system, all designed to empower veterinarians to provide top-tier care. In the aggregate, their total addressable market in the U.S. exceeds
Follow Zomedica
Email Alerts: http://investors.zomedica.com
Facebook: https://m.facebook.com/zomedica
X (formerly Twitter): https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Cautionary Note Regarding Forward-Looking Statements
Except for statements of historical fact, this news release contains certain "forward-looking information" or "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur and include statements relating to our expectations regarding future results. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance, or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.
Forward-looking information is based on the opinions and estimates of management at the date the statements are made, including assumptions with respect to economic growth, demand for the Company's products, the Company's ability to produce and sell its products, sufficiency of our budgeted capital and operating expenditures, the satisfaction by our strategic partners of their obligations under our commercial agreements and our ability to realize upon our business plans and cost control efforts.
Our forward-looking information is subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: the outcome of clinical studies, the application of generally accepted accounting principles, which are highly complex and involve many subjective assumptions, estimates, and judgments, uncertainty as to whether our strategies and business plans will yield the expected benefits; uncertainty as to the timing and results of development work and verification and validation studies; uncertainty as to the timing and results of commercialization efforts, including international efforts, as well as the cost of commercialization efforts, including the cost to develop an internal sales force and manage our growth; uncertainty as to our ability to realize the anticipated growth opportunities from our acquisitions; uncertainty as to our ability to supply products in response to customer demand; supply chain risks associated with tariff changes; uncertainty as to the likelihood and timing of any required regulatory approvals, and the availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; veterinary acceptance of our products and purchase of consumables following adoption of our capital equipment; competition from related products; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; our ability to secure and maintain strategic relationships; performance by our strategic partners of their obligations under our commercial agreements, including product manufacturing obligations; risks pertaining to permits and licensing, intellectual property infringement risks, risks relating to any required clinical trials and regulatory approvals, risks relating to the safety and efficacy of our products, the use of our products, intellectual property protection, and the other risk factors disclosed in our filings with the SEC and under our profile on SEDAR+ at www.sedarplus.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.
The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.
Investor Relations Contact:
Zomedica Investor Relations
investors@zomedica.com
1-734-369-2555
SOURCE: Zomedica Corp.
View the original press release on ACCESS Newswire
FAQ
What is new about Zomedica's TRUFORMA Cobalamin & Folate assay in 2025?
How long does the TRUFORMA Cobalamin & Folate test take to deliver results?
Why is rapid Cobalamin & Folate testing important for cats?
How can veterinarians access Zomedica's TRUFORMA Cobalamin & Folate test?
When was the TRUFORMA Cobalamin & Folate assay first launched for dogs?
